Academy Capital Management Inc. TX decreased its stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) by 1.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 622,146 shares of the specialty pharmaceutical company’s stock after selling 6,857 shares during the quarter. Valeant Pharmaceuticals Intl makes up approximately 3.6% of Academy Capital Management Inc. TX’s investment portfolio, making the stock its 15th largest position. Academy Capital Management Inc. TX’s holdings in Valeant Pharmaceuticals Intl were worth $12,928,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. grew its position in shares of Valeant Pharmaceuticals Intl by 118.2% in the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock valued at $119,000 after purchasing an additional 4,512 shares during the period. Traynor Capital Management Inc. acquired a new stake in shares of Valeant Pharmaceuticals Intl in the fourth quarter valued at about $213,000. Stephens Inc. AR acquired a new stake in shares of Valeant Pharmaceuticals Intl in the fourth quarter valued at about $222,000. Cetera Investment Advisers acquired a new stake in shares of Valeant Pharmaceuticals Intl in the second quarter valued at about $192,000. Finally, Gamco Investors INC. ET AL acquired a new stake in shares of Valeant Pharmaceuticals Intl in the fourth quarter valued at about $249,000. Institutional investors and hedge funds own 48.49% of the company’s stock.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) opened at $18.03 on Tuesday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. Valeant Pharmaceuticals Intl Inc has a 52 week low of $8.31 and a 52 week high of $24.43. The company has a market cap of $6,290.00, a PE ratio of 4.62, a price-to-earnings-growth ratio of 0.56 and a beta of -0.42.

In other news, Director John Paulson bought 344,216 shares of Valeant Pharmaceuticals Intl stock in a transaction on Thursday, November 16th. The shares were bought at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the purchase, the director now directly owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.87% of the stock is owned by insiders.

Several analysts have recently issued reports on the stock. Goldman Sachs Group assumed coverage on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, January 24th. They issued a “sell” rating and a $18.00 target price on the stock. Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research report on Friday, January 19th. Wells Fargo & Co restated a “sell” rating and set a $9.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, January 16th. HC Wainwright boosted their price target on shares of Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Finally, Zacks Investment Research lowered shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 13th. Seven research analysts have rated the stock with a sell rating, nine have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $18.59.

TRADEMARK VIOLATION NOTICE: This news story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://theolympiareport.com/2018/02/13/valeant-pharmaceuticals-intl-inc-vrx-shares-sold-by-academy-capital-management-inc-tx.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.